Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Post by pabalooon Mar 03, 2021 1:32pm
165 Views
Post# 32706173

Just a heads up.

Just a heads up.All there irons in the fire don't add up to the loss of Absorica royalty they will start to loose as of December.  They have only made public that it will be descending. Once all the scripts are changed to the LD version Generic won't matter anyway no one will want it. That puts Sun in the driver seat, not Cipher. Trevyent may not even pass FDA and the royalties on that are minimal. Trulance was the saviour here. It was huge!! I love the way they say it want part of there revenue anyway. It was the only reason to hold this stock! It was the future. Have you looked at what there pipeline looks like now? Friggen tattoo cream that maybe 10 years from anything? How about a nail fungus cure that is having trouble getting approval if it ever does? The future is not bright the stock is worth .48 cents by my numbers. Please tread carefully it doesn't have a debt and holds some cash the rest is falling fast.  Do your own DD good luck. Just trying to help I'm not a basher! I owned the stock for a year when it hit .40 cents everyone made money at that time. Should have fold earlier than I did I trusted management on the Trulance suit and they let every share holder down without explanation. I may join the next conference call to ask the question who dropped the ball. I want to hear them babble there bull.
<< Previous
Bullboard Posts
Next >>